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a transient increase in transaniinases was observed (less than X 3  
baseline value). Mean follow-up of patients from the start of 
DOTCH was 2 7 0 t 3 5  days 
Conclusions: IVDUs on a methadone program are at high risk 
of tuberculosis because of the high incidence of tuberculous 
infection. In this population, to assure good adherence, directed 
observed prophylaxis is needed; probably (study still ongoing), INH 
twice a week is cost-effective. In our present experience, tolerance 
and adherence are quite satisfactory. 
Viral diagnostics 
Laboratory diagnosis of hepatitis B virus (HBV) 
infection: the role of serum HBV-DNA 
assessment. 
M. Saber’, H. Badawey’, M. Onia?, A. Abu-Aitta’, M. El- 
Hamshary ’ . ‘Bioclienristry and ’A4icrobiolqy Deparhncrits, Theodor 
Bilharz Research Institute, Egypt 
Objectives: (1) To assess the role ofHBV-DNA in diagnosis ofHBV 
infection. (2) To study the distribution of different HBV serologic 
profiles among acute and chronic hepatitis B cases. (3)  To evaluate 
the diagnostic efilciency of different assays for serodiagnods of HBV 
infection. 
Methods: Serum samples from 100 HBV cases were studied for 
HBV markers (HBsAg/Ab, HBeAg/Ab, HBctotal/IgM) using 
ELISA, Dot-ELISA and ininiunodiffusion techniques. HBV-DNA 
was studied by the spot hybridization method. 
Results: HBV-DNA was detected in 96.7% of acute and 29.6% 
of chronic cases. HBeAg minus profile represents 41.3% of acute and 
75% of chronic hepatitis B cases. Dot-ELISA showed 100% sensitiv- 
ity and 98.3% specificity as compared with ELISA test. 
Conclusions: Significant correlation was found between HBV 
viremia and HBV-DNA positivity The HBeAg minus mutant of 
HBV characterizes the major infective agent in HBV infection in 
Egypt. Dot-ELSA can substitute for conventtoiial ELISA, especially 
in screening large numbers of samples. 
lp455) Molecular characterization and sequence 
stability of the hepatitis B virus surface gene in 
children treated with interferon 
H.-F. Liu’, E. Sokal’, P. Goubau’. Utzits .f ’Virology a n d  ’Pcdiatrir 
Gastroenterolqqy 6 Hepatology, University Hospital St-Lur, Uirivcrsity of 
Lotciain, Bnrsse~s, Be[qiirm 
Objectives: To investigate the stability of hepatitis B virus (HBV) 
surface (S) gene in 23 children under interferon (IFN) treatment in 
Belgium by comparing the sequence of serial saniples taken before 
and after treatment. We also studied HBV genotypes and serotypes 
in this patient population. 
Methods: A 736-bp fragment spanning the 3-end of pre-S and 
almost the entire S genes of the HBV genome was amplified and 
sequenced. Together with other strains ofdifferent geographic origin, 
phylogenetic analycis was performed using three different methods. 
Results: Twelve of the 23 pediatric patients were found to have 
a response to IFN treatment. Except for 4 patients, no sequence 
change was observed before and after IFN treatment. These DNA 
sequence changes (or mixed nucleotides) did not change the amino 
acid sequences of the HBsAg and the polymerase in 3 patient$. The 
other strain has mixed nucleotides which encode two different amino 
acids. Four different genotypes (A, B, I), E) were f&nd among the 
23 patients. Most of them were types A and D. 
Conclusions: A great genomic sequence stability of the S gene 
was found under IFN treatment. The high diversity of HBV grno- 
types reflects the fact that most children are adopted and  is concor- 
dant with their geographic origin?. The response to IFN treatment 
is not correlated to HUV genotypes. 
Lp4561 IMMULITE Anti-HBc for detection of serum IgM 
M. Ghadessi, J.-D Lei, D. Sustarsic, A.S. El Shanii, Diajriosrir 
Prodircts Corp., Researrh and Develiipntent, Los Any&c, CA, I JSA 
Objectives: IMMULITE Anti-HBc IgM is a n  automated, solid- 
phase, two-step cheniiluminescent enzyme inimunoacsay. The 
purpose of this study was to evaluate the perforinance of the 
lMMULlTE Anti-HBc IgM against another EIA assay. 
Methods: Enclosed within the proprietary IMMULITE Test 
Unit is a polystyrene bead coated with a niurine monoclonal anti- 
body specific for IgM. Patient sample and buffer reagent are simul- 
taneously introduced automatically by the IMMULITE into the test 
unit and incubated for 30 min. After a spin-wash, sample, cxcess 
reagent and wash solution are captured in a coaxial waste chamber. 
An alkaline phophatase-labeled recombinant HBcAg is then added. 
Following another 30 min of incubation and wz\h, enzyme label ic 
measured with a cheniiluminescent substrate, a phosphate ester of 
adniantyl dioxetane. A quantitative result is obtained by coinparing 
the patient result to an internal standard curve calibrated to the PEI. 
A collection of 155 seruni samples was tested by both the 
IMMULITE and Abbott Corzyme-M (rDNA) assays. 
Results: The relative sensitivity and specificity values for the 
IMMULITE assay were 90.3% and 97.6% in comparison to the 
Corzyme-M assay, with 95.5% agreement between the two assays 
Conclusion: The excellent performance characteristics of the 
IMMULITE Anti-HBc IgM assay make it suitable for use in the diag- 
nosis of acute or recent hepatitis B viral infections. 
lp4571 Comparison of IMMULITE 2000 Anti-HBc to 
Abbott 
D. Burns, C. Ccrvantes, R. Gonzalez, M. Ghadessi, S. El Shami. 
Diqrrostir Prodiirts Corporarioii, L i s  Anjeies, CA, LX4  
Objectives: To evaluate the performance characteristics of the 
IMMULITE 2000 Anti-HBc assay (Thgnostic Products Corpor- 
ation, Los Angeles, CA) for detection of total antibodies to hepatitis 
B core antigen (anti-HBc). 
Methods: The performance of IMMULITE 2000 Anti-HBc was 
compared to the Abbott CORZYME assay (Chicago, IL) using the 
Anti-HBc Total Sensitivity Panel (PHG804) and Anti-HBc Total 
Mixed Titer Performance Panel (PHG201) purchased from Boston 
Bioniedica, Inc. (west Bridgewater, MA). 
Results: The Anti-HBc Total Sensitivity Panel (PHG804) and 
Anti-HBc Total Mixed Titer Performance Panel (PHG201) were 
evaluated with the IMMULITE 2000 Anti-HBc and the Abbott 
CORZYME assays. Based on the sensitivity panel, the IMMULITE 
2000 assdy was sensitive to 1.5 Paul Erhlich Institute (PEI) units/mL. 
In comparison, the Abbott assay detected total anti-HUc down to 1 .O 
PEI U/mL. The difference in functional sensitivity was nlininial as 
noted in the comparison between the two assays on thr mixed titer 
perforinance panel. The results from the mixed titer performance 
panel demonstrated that the IMMULITE 2000 .issay correlated well 
with the Abbott CORZYME assay, with 100% agreement. 
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Conclusion: The performance of the IMMULITE 2000 Anti- 
HBc assay was shown to be equivalent to that of the Abbott 
CORZYME assay, and it is an effective method for detection of anti- 
bodiey to hepatitis B core antigen. 
[p4581 Evaluation of the IMMULITE 2000 HBsAg assay 
D. Burns, C. Cervantes, R. Gonzalez, S. El Shami. Diagnostic. 
Products Corporation, Ds Anples, CA, U S A  
Objectives: To evaluate the performance characteristics of the 
IMMULITE 2000 HBsAg assay (DPC, Los Angeles, CA) for detec- 
tion of hepatitis B surface antigen (HBsAg). 
Methods: The performance of IMMULITE 2000 HBsAg was 
compared to Abbott AUSZYME (Chicago, IL) using commercially 
available HBsAg seroconversion panels, HBsAg sensitivity panel, and 
HBsAg low and mixed titer performance panels (Boston Biomedica, 
Inc., West Bridgewater, MA). 
Results: Four HBsAg seroconversion panels (PHM911 and 
PHM922 for subtype ad; PHM902 and PHM907 for subtype ay), 
sensitivity panel PHA806, low titer performance panel PHAl 05 and 
mixed titer performance panel PHA204 were evaluated with the 
IMMULITE 2000 HBsAg and the Abbott AUSZYME assays. With 
two of the seroconversion panels, IMMULITE 2000 and Abbott 
performed identically, detecting HBsAg on bleed days 50 and 79 with 
panels PHM907 and PHM911, respectively. With panel PHM902, 
IMMULITE 2000 detected HBsAg one bleed day earlier than 
Abbott. With panel PHM922, Abbott detected HBsAg one bleed 
day earlier than IMMULITE 2000. With the sensitivity panel, 
IMMULITE 2000, similar to Abbott, detected concentrations of 
HBsAg as low as 0.03 Paul Ehrlich Institute (PEI) units/mL. With 
respect to the low and mixed titer performance panels, the 
IMMULITE 2000 had 100% agreement with the Abbott assay. 
Conclusions: The performance of the IMMULITE 2000 HBsAg 
is equivalent to that of the Abbott AUSZYME assay and it is an effec- 
tive method for diagnosis of acute HBV infections. 
1-1 Comparison of IMMULITE 2000 Anti-HBs to 
Abbott 
C. Cervantes, 1). Burns, R. Gonzalez, S. El Shanu. Diagnostic 
Products Corporation, Lor Angelcs, CA, U S A  
Objectives: To evaluate the performance characteristics of the 
IMMULITE 2000 Anti-HBs assay (Diagnostic Products Corpor- 
ation, Los Angeles, CA) for detection of antibodies to hepatitis B 
surface antigen (anti-HBs). 
Methods: The performance of IMMULITE 2000 Anti-HBs was 
compared to the Abbott AUSAB kit (Chicago, IL) using the 
commerically available Anti-HBs Sensitivity Panel (PHCBOI) and 
Anti-HBs Mixed Titer Performance Panel (PHC201) (Boston 
Biomedica, Inc., West Bridgewater, MA). 
Results: The Anti-HBs Sensitivity Panel (PHC801) and Anti- 
HBs Mixed Titer Performance Panel (PHC201) were evaluated with 
the IMMULITE 2000 Anti-HBs and the Abbott AUSAB assays. The 
results obtained by the IMMULITE for the mixed titer performance 
panel were equivalent to those results obtained by the Abbott assay, 
with the exception of two samples. The two discrepant samples were 
resolved by additional reference methods. With the sensitivity panel, 
both the IMMULITE 2000 and Abbott assays detected anti-HBs 
down to 10 mIU/mL, the recognized cut-off for immunity to hepati- 
tis B. 
Conclusions: The performauce of the IMMULITE 2000 Anti- 
HBs assay was shown to be equivalent to that of the Abbott AUSAB 
assay, and these results indicate that the IMMULITE 2000 assay is an 
effective method for detection of antibodies to hepatitis B surface 
antigen. 
[p460] The importance of HCV antigen presentation 
for assay seroconversion sensitivity 
S. Tirrell', \9! Zeigler', D. Chien*, C. Fang', M. Jackson', S. 
Quan2, H. Zazulak', L. Baker'. 'Chiron Diagnostics Corporation, East 
Wafpok ,  M A ,  'Emeryville, CA, U S A  
Objectives and methods: HCV seroconversion panels reflect 
biological diversity in immune response to the core, NS3, NS4 and 
NS5 regions of the HCV genome during early infection. The 
immunoblot (RIBA HCV 3.0 SIA) patterns on 37 seroconversion 
panels were examined and correlated to the sensitivity of three 
immunoassays: (1) Ortho HCV 3.0 EIA, (2) Abbott HCV 2.0 EIA, 
and (3) Chiron ACS:Centaur HCV assay (chemiluminescent 
immunoassay utilizing NS3 antigen and a multiepitope fusion anti- 
Results: For the 11 panels with a single core band first, the Chiron 
assay showed positive results earlier on three, equal on six and later 
on two panels when compared to the other two assays. For the 17 
panels with a single NS3 band first, positive results by Chiron assay 
were ahead of Ortho assay on eight and equal on nine panels, while 
both assays were ahead of Abbott assay on all 17 panels. Overall, the 
Chiron assay detected specific antibodies earlier than Ortho assay on 
eight panels and Abbott assay on 20 panels, but later than these two 
assays on two panels. 
Conclusions: (1) RIBA data show that nearly 97% (36/37) of the 
HCV seroconverters produced detectable antibodies to core and/or 
NS3 antigens first and none produced antibodies to NS5 first; (2) 
though all three assays utilized antigens from major epitopes of core 
and NS3, the Chiron assay demonstrated a better overall seroconver- 
sion sensitivity than the other two assays; therefore (3) assay sero- 
conversion sensitivity appears to be mainly affected by presentation 
of antigens and assay format. 
gen). 
m] HCV NS3 protein conformation in liquid phase 
is essential for early seroconversion detection 
W. Zeigler', D. Chien', S. Lauzier', S. Emrich', M. Corkery', F? 
Franchi', L. Baker', S. Tirrell'. 'Chiron Diagnostics Corporation, East 
Walpole, MA, 'Emeryville, CA, U S A  
Objectives: Since 62.5% (20/32) of commercial seroconversion 
panels examined showed NS3 seroreactivity as one of the first bands 
to appear on an HCV recombinant immunoblot assay (RIBA HCV 
3.0 SIA), the importance of NS3 conformation was examined. 
Methods: An automated, high-throughput HCV chemilumines- 
cent imniunoassay system, the ACSCentaur, utilizes paramagnetic 
microparticle technology which allows rapid antigen-antibody inter- 
action in a liquid phase. The stability of the liquid-phase conforma- 
tion of an NS3 recombinant protein, c33c, is important to maximize 
the sensitivity for early seroconversion detection. Maintaining this 
c33c conformation in liquid phase was accomplished by adding 
reducing agent in the reagent buffer so that detection of seroconver- 
sion was maximized and stabilized. 
Results: This activity was monitored with two seroconversion 
panels that demonstrated antibody reactivity to c33c prior to ocher 
HCV proteins on RIBA. When c33c was stored in buffer without 
reducing agent, more than 50% of the assay seroconversion activity 
was reduced within hours. When c33c was stored in buffer with 
reducing agent, most of the seroconversion activity was maintained 
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beyond 21 days at 37°C. Sensitivity was further evaluated with 18 
seroconversion panels demonstrating aiiti-c33c reactivity first on 
RIBA. Detection of seroconversion was earlier on 8 panels and equal 
on 10 panels when compared to the Ortho HCV 3.0 EIA where the 
sanie NS3 protein is immobilized onto a solid phase. 
Conclusions: The data demonstrate that the NS3 protein confor- 
mation is stabilized in liquid phase by addition of a reducing agent 
which is essential for maintaining maximum assay seroconversion 
sensitivitv. 
lp462) Heteroduplex mobility assay (HMA) as a tool 
for the evaluation of genomic variability of 
hepatitis G virus 
E Garcia, E Garcia Jr, I. Lbpez, M.C. Bernal, €? Morata, G. 
Pibdrola, M.C. Maroto, School ojhfediciwe, Microbioloxy, Granada, 
Spairr 
Objectives: To apply the experimental model for the study of 
genoinic variability of hepatitis C virus (HCV) for determination of 
quasispecier in hepatitis C; virus (HGV). 
Patients and methods: 13 samples of 4 patients with chronic 
hepatitis C were obtained at 0, 4, 8 and 12 months of treatment with 
IFN; and 5 basal samples from 5 patients, two of them co-infected 
by HIV, with chronic hepatiti5 G, where HGV-RNA w a s  detected 
by two different P C R  techniques. For the study of HCV quari- 
species, KT-nested PCR of the El-HVK region was performed. For 
HGV quasispecies, RT-boosted PCR of the NS3 region was 
performed. The amplified products were analyzed by HMA. 
Results: HCV quasispecies appeared in 3 of 4 basal samples. In 
two cases these quasispecies disappeared in the next samples during 
treatment, and in one case a quasispecies appeared but later disap- 
peared. For HGV, quasispecies were detected in 4 of 5 patients. 
Conclusions: When we apply the model for study of HCV quasi- 
species to HGV we find a high genomic variability for this virus in 
its NS3 region. This could be a very important finding for the knowl- 
edge of the molecular biology and pathogenicity of a virus as recently 
discovered as the hepatitis G virus. 
rp4631 Detection of viremia and antibodies in 
hepatitis G virus infection in different 
population groups from southern Spain 
F. Garcia, 1. Lbpez, F. Garcia Jr, M.C. Bernal, P. Morata, J. 
Her ihdez ,  J. Garcia-Valdecasas, G. Pikdrola, M.C. Maroto, School 
cf Medicine, Microbiolo,qy, Granada, Spain 
Objectives: To evaluate the seroprevalence and viremia of the 
hepatitis G virus (HGV) among different population groups in south- 
ern Spain. 
Patients and methods: 277 serum sampler, from 69 patients 
under heniodidysis, 104 from a healthy population, and 104 samples 
from patients infected by human immunodeficiency virur. All 
saniplcs were tested for HGV viremia by two tests, one amplifying 
the S'UTR region (Abbott LCx GBV Assay), and another aniplify- 
ing the NS3 region (LhSorin HGV-RNA Assay), as well as for HGV 
antibodies (Boehringer-Manheiin anti-Hgenv). 
Results: HGV-KNA was considered positive only on concordant 
samples by both methods. For patients under hemodialysis, viremia 
was detected in 7 patients (10.1%) while 20 patients were positive for 
anti-HGenv antibodies (29.0%); for the general population, 7 patients 
were vireinic (6.7%), while 13 (12.5%) showed detectable antibod- 
ies; finally, for HIV-infected patients, 15 patients were previously 
known as positive for HGV-RNA and 42 patients (40.3%) were 
found positive by serology. Only 3 patients (2 under hemodialysis 
and 1 HIV infected) were found positive for both vireniia and anti- 
bodies. 
Conclusions: Viremia and antibody response In HGV-infected 
patients are generally not detected at the same time. suggesting that 
seroconversion inay be a good prognostic factor for HGV infection. 
The high prevalence of HGV in HIV-infected patients may favor the 
parenteral transmission route of this virus. 
lp4641 Cobas Core Anti-HBs Quant EIA II: performance 
of a novel enzyme immunoassay with an 
extended measuring range 
W. Schuinacher, B. Satzinger, H. Andres, M. Zauke. Rorlre 
Diagnostics, Penz6cy,  Germany 
More than 300 million persistent HBV carriers worldwide represent 
a permanent source of infection. Active prophylaxis against HBV 
infection is available as HBV surface antigen (HBrAg) vaccines. The 
level of anti-HBs antibodies indicates duration of protection or 
recovery from a past infection. 
A Cobas Core two-step double antigen Fandwich EIA was devel- 
oped for quantification of anti-HBs in rerum or plasma. Detection 
of anti-HBs against HBsAg subtypes ad and ay is based on hpHBsAg 
immobilized on polystyrene beads. Bound antibodies are labeled by 
hpHBsAg conjugated to horseradish peroxidase and quantitated by a 
chromogenic enzyme substrate. 
In comparison to the currently marketed quantitative one-step 
Cobas Core Anti-HBs EIA, the measuring range was extended up to 
1000 niIU/niL. The assay is WHO-calibrated and requires a 1 -point 
recalibration. Concentrations are calculated from a master curve by 
the instrument. W H O  samples gave a mean concentration recovery 
of 99.7%). The assay has a perfectly low detection limit of 0.2 
mlU/mL. CV values <5% indicate a high degree of reproducibility. 
Dilution series of positive sera gave a mean recovery of 99.8'%. A 
method comparison to Abbott AxSYM AUSAB demonstrated a 
good agreement of quantitative results with a correlation coefficient 
of 0.97 and a regression slope of 1.04. The diagnostic sensitivity was 
100% and the diagnostic specificity was 99.5%. 
The excellent performance of the Anti-HBs Quant EIA I I  in 
combination with the high throughput of the fully automated Cobas 
Core immunoanalyzer offers the user an effective means to monitor 
the presence of anti-HBs after vaccination or natural infection. 
lp4651 Detection of herpes simplex encephalitis (HSE) 
by using polymerase chain reaction (PCR) 
assay in cerebrospinal fluid samples (CFS) 
C. Nogueira, G. Marrao, G. Rocha, A.C. Magalhaes-Sant Ana. 
University cf Coinibra, Faculty cfiwedicine, Coimbria, Portugal 
Objectives: Determination of a specific and early diagnosis for HSE. 
Methods: The P C R  is a method by which very small quantities 
of DNA can he enzymatically amplified in vitro In this study CFS 
samples from 57 patients with clinically suspected HSE were tested 
by PCR assay and identified by electrophoresis and immunornzy- 
niatic hybridization. 
Results: Only 2 of the 57 samples of CSF gave a positive result 
in this assay. 
One of the 2 cases was an 1 I-year-old boy with fever, convulsion, 
apnea and transient disorientation. He underwent electroencephalo- 
graphy (EEG) and cranial nuclear magnetic resonance (NMR). EEG 
demonstrated abnorinalities compatible with infections encephalitis. 
N M R  did not show significant brain alterations. The patient had 
208  Cl in ica l  M i c r o b i o l o g y  and  In fec t ion ,  Vo lume 5 Supp lement  3 
been treated with intravenous acyclovir for 10 days with good reso- 
lution. 
The other case was a 15-month-old female child with fever, 
altered consciousness, convulsion and a right hemiparesis. She under- 
went EEG, which did not reveal significant abnormalities. This 
episode had a good resolution without therapy with acyclovir. 
Conclusions: We conclude that PCR assay is a reliable tool for 
the early diagnosis of HSE, thus favoring a better outcome for 
patients with this disease. 
v1 Improved diagnosis of herpesvirus infection of 
the central nervous system by nested 
polymerase chain reaction 
E. Arrese’, M. Basaras’, M.J. Fernandez’, M. Imaz2, R. Cisterna’,2. 
‘University of Basque Courztry, ’Basurto Hospital, Bilbao, Spain 
Herpesviruses are an important cause of central nervous system 
(CNS) infections. Standard laboratory techniques, such as viral 
culture, rarely recovered herpesviruses in cerebrospinal fluid (CSF), 
and the sensitivity of the serology for rapid diagnosis of CNS infec- 
tions is very low. As an alternative to these techniques, recently, the 
polymerase chain reaction (PCR), allowing the detection of 
herpesvirus DNA in CSF samples, has been shown to be a promis- 
ing diagnostic tool. In this study, we performed nested PCR for the 
detecoon of five herpesviruses: herpes simplex virus (HSV), varicella- 
zoster virus (VZV), cytomegalovirus (CMV), human herpesviruses 6 
(HHV-6) and Epstein-Barr virus (EBV) in CSF. 
Methods: A total of 102 CSF samples from patients with sus- 
pected herpesvirus infection in the CNS were analyzed for the pres- 
ence of HSV, WV, CMV, HHV-6 and EBV DNA by nested PCR 
(Radar-Real). The extraction of nucleic acids from CSF samples was 
performed with proteinase K. For the first amplification, primers 
were used as two equimolar mixtures of non-degenerate oligonu- 
cleotides. In the second amplification, primers produce different-size 
fragments for each related virus. Amplified products were analyzed 
by electrophoresis on agarote gel containing ethidiuni bromide and 
visualized under W light. 
Results: DNA of herpesvirus was detected in CSF from 16 of the 
102 patients with neurologic disease. HSV DNA was detected in 1 
patient, WV DNA was detected in 4 patients, CMV DNA was 
detectable in CSF from 7 patients, HHV-6 DNA was detected in 1 
CSF sample and EBV DNA was detected in 3 patients. 
Conclusions: The rapid, and non-invasive diagnosis of herpes- 
virus infection of the CNS by amplification of the viral genome in 
CSF provides a sensitive diagnostic tool. 
lp4671 The investigation of herpes viruses by PCR in 
patients with aseptic meningitis 
E Yarkin’, D. Ufuk’, N. Saltoglu’, F. Koksal’. ‘Microbiobgy 
Department, zlnfectious Diseases Department, Faculty of Medicine, 
University of Cukurova, Adana, Turkey 
Objectives: To determine the incidence of human herpes viruses by 
PCR in adult patients with aseptic meningitis in this study. 
Methods: The diagnosis of aseptic meningitis was based on clin- 
ical findings and biochemical analyses of cerebrospinal fluid (CSF). 
The CSF samples from 26 adult patients were evaluated by PCR with 
herpes consensus hybridowell, human herpes virus amplification kit 
(Angers Biosoft, reference:67-013A) and human herpes virus identi- 
fication kit (Argene Biosoft, reference:67-013). This kit allows the 
detection of HSV1, HSV2, CMV, EBV, VZV and HHV-6 in clini- 
cal samples. The study was performed in two steps as amplification 
and hybridization. In the first step, the amplification ofa 320-bp frag- 
ment located in the DNA polymerase gene that is conservative and 
genus specific was performed. In the second step, the amplified prod- 
uct was analyzed by hybridization in a microtiter plate with six 
biotinylated oligonucleotide probes specific for the six viruses. 
Results: HSVI DNA was determined in 4 (15.3%) of 26 CSF 
samples and HHV-6 DNA was determined in 1 (3.8%) sample. 
Conclusions: The PCR method performed with herpes consen- 
sus hyhridowell kit in the diagnosis of herpes virus meningitis should 
be considered as an alternative method. 
[p4681 Sensitivity of recombinant antigens to detect 
antibody responses to cytomegalovirus in 
transplant recipients 
D.W. van Dam, A.C.M. Kroes, Leiden University Med.  Center, 
Virology, Leiden, The Netherlands 
Objectives: To compare the relative sensitivities of newly developed 
recombinant antigens and conventional antigens applied in commer- 
cial assays for antibody detection to cytomegalovirus (CMV), in 
confirmed primary infections post-transplantation. 
Methods: Transplant recipients were included consecutively, if 
they were initially CMV seronegative (Abbott AxSYM IgG) and 
grafted with an organ from a CMV-seropositive donor. CMV infec- 
tion was documented by viral pp65-antigen detection in leukocytes. 
191 samples from 21 patients (mean, 9.1 samplelpatient) were 
analyzed by eight commercial assays from Abbott, Biotest, bio- 
Merieux and Organon Teknika. Four assays applied recombinant 
CMV antigens and four conventional antigens, detecting either IgG, 
IgM or IgA. Results were compared by the first day of detectable 
antibody for each patient in a rank order analysis, which for compar- 
ison also included the viral antigen detection. 
Results: In 18 (of 21) patients, viral antigen detection was posi- 
tive before seroconversion in any assay. Scoring the time to a first 
positive result demonstrated the three most sensitive assays employed 
conventional antigens and the three least sensitive assays used recom- 
binant antigens. This was also evident from graphical analysis of 
cumulative seroconversion rates. Analyzing individual patients, 
heterogeneity was observed in the results of recombinant antigen 
assays, reactivity being either brisk or slow and low. 
Conclusions: Serologic assays applying recombinant CMV anti- 
gens did not demonstrate earlier seroconversion, compared to those 
applying conventional antigens in a population of transplant recipi- 
ents. In a primary response, not all viral epitopes are involved simul- 
taneously, which may offer an advantage to the broader antigenic 
composition of conventional antigens. This may represent a limita- 
tion of using a small set of recombinant antigens in serologic tests. 
lp4691 Evaluation of the Abbott AxSYM/IMx 2.0 CMV 
IgM assays 
G. Maine, R. Stricker, M. Schuler, J. Spesard, D. Wachta, H. 
Simmons, K. Henvig, T. Lazzarotto, A. Ripalti, M.P. Landini, 
Abbott Laboratories, Dept .  9JU: Abbott Park, IL, USA 
Objectives: To determine the performance characteristics of the 
new Abbott AxSYM/IMx 2.0 CMV IgM assays in a clinical evalua- 
tion relative to a consensus interpretation of three legally marketed 
tests (Abbott CMV-M EIA, Trinity Biotech CAPTIA CMV-M, and 
Gull CMV IgM ELISA). The AxSYMlIMx 2.0 assays utilize recom- 
binant CMV antigens (pp150, pp65, pp52, and pp38) for CMV IgM 
detection. 
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Methods: A total of 993 serum specimens (fresh and frozen) were 
tested from the following individuals: 200 random volunteer blood 
donors (fresh); 599 pregnant women (fresh); 42 suspected CMV 
IgM-positive individuals (frozen); serial bleeds from 44 woniedpreg- 
nant women (152 specimens in total) in which 27/44 individuals had 
documented seroconversion to CMV IgG (frozen). Specimens with 
discordant results were further tested with a CMV IgM innnunoblot. 
Results: The following performance characteristics were deter- 
mined after resolution of specimens with discordant results (n=841 
specimens), For AxSYM the relative sensitivity, specificity and agree- 
ment were 100%, 97.5% and 97.6%, respectively For IMx 2.0 the 
relative sensitivity, specificity and agreement were loo'%,, 97.9'?+ and 
98.0% Both assays can detect early seroconversion (when the first 
bleed in a series from an individual with documented seroconversion 
was IgG negative). 
Conclusions: The new recombinant antigen-based Abbott 
AxSYM/ IMx 2.0 CMV IgM assays are sensitive and specific tests for 
the detection of CMV IgM in pregnant women. 
IP470] Detection of Cytomegalovirus (CMV) pp67 
late gene transcripts and quantitation of hiv-1 
viral load by nasba in cerebrospinal fluid: 
correlations with CNS disease in AIDS patients 
C.C. Ginocchic)', E Zhang', S. Tetali'. M.H. Kaplan', F. 
Cromme', J. Lunenberg-'. 'Norrh Shore Uniirrsity Hospital, NI'LJ 
School qfhfedicinc, Alanhasset, &'I: 'Oyunun Teknika BL,' B o d ,  NI,' 
us.4 
Objectives: To evaluate CSF detection of CMV pp67 late gene tran- 
scripts and CSF HIV-1 viral load measurements as aids for the differ- 
ential diagnosis of CMV encephalopathy and AIDS dementia 
complex (ADC) in HIV+ patients. 
Methods: CMV pp67 detection and CSF viral loads were per- 
formed using nucleic acid sequence-based amplification (NASBA) 
assay5 on 75 CSFs from 63 patients diagnosed with a variety ofAIDS- 
related neurologic diseases. 
Results: The mean CSF viral loads (log KNA copies/ mL) were 
significantly higher in patients with ADC (5.27 log) than in patients 
with neuro-CMV (4.44 log), other CNS disease (4.59 log) or no 
CNS disease (3.39 log). CMV detection by the pp67 assay was 
compared to DNA nested PCR and viral culture. 56/61 CSFs from 
patients without CMV CNS disease were negative by PCR (5 posi- 
tive), 61/61 negative by NASBA, and 44/44 negative by culture. 14 
CSFs from 12 patients suspected of having neurologic disease due to 
either CMV, ADC or both yielded the following results: CMV 
culture+ 2/14; PCR+ 14/14; NASBA+ 9/14. Based upon clinical, 
laboratory and radiographic studies and review of antiviral therapy, 
resolution of the 10 discordant PCR and NASBA results yielded the 
following positive (PPV) and negative (NPV) predictive values for the 
diagnosis of neuro-CMV disease: PPV-DNA PCR (73.7'%), pp67 
Conclusions: This study indicates that CSF viral load and the 
detection of CMV pp67 transcripts both provide valuable informa- 
tion for the differential diagnosis of ADC and CMV CNS disease. 
(1OO'Yu); NPV-DNA P C R  (loo%), pp67 (95.5%). 
CMV infection-comparison of laboratory 
methods 
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Objectives: To compare different laboratory methods to determine 
the best method for diagnosis of CMV in renal transplant recipients. 
Methods: ELISA (IgG, IgM), Western blot, shell vial, antigcne- 
mia assay (pp65), the immunofluorescent method with epithelial cells 
from urine (IF), I'CK and hybridization (HCS). 
Results: Samples &on1 the 17 consecutive renal transplant recip- 
ients were taken on the day of transplant and 5-6 times during the 
first 3 postoperative months (mean time 95.5 days). CMV infection 
was confirmed by at least one method i n  all patient\. Thref patients 
were diapoyed by five methods, 4 patients by four niethods, 3 
patients by three methods, 6 patients by two methods and 1 patient 
by one method. In groups in which mfection was confirmed by five 
and four methods all patients were diagnosed by HCS and We\tcrn 
blot, but in other groups the pp65 assay was mostly used. A clinicd 
manifestation of CMV infection was observed in 3 patients. Only 
results obtained using PCR and HCS were statistically correlated 
with syniptomatic CMV infection (p<l).UOOOl). Coinparisons ofthe 
capacity of these tests to diagnose symptomatic infection show the 
highest specificity and positive predictive value for HCS, especlally 
for DNA levels greater than 60 pg/nlL (99% and 89% respectively). 
In patients with no CMV infection, HCS was always negative, wlth 
CMV DNA level below 8 pg/mL of blood. 
Conclusions: The presented study shows that HCS, PCR and 
Western blot are sensitive methods for detecting CMV infection. 
Using HCS in quantitative variant we obtained a very good correla- 
tion between DNA load and clinical syniptoms. 
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Objectives: In the past, several real-time PCK cyctems havc been 
established for the quantification of important microbiological 
pathogens. Accurate quantification by this method is dependent on 
the precke binding of primers and probe. which might be a Iiinita- 
tion for quantification of microorganisms with high mutation rxes. 
We were interested in effects of these mutations in the primer or 
probe binding region and have investigated their influence on the 
results of the quantification. 
Methods: For this purpose we have used a feline immunodefi- 
ciency virus (F1V)-specific real-time P C R  system. In previous stud- 
ies we were able to demonstrate the high sensitivity (5 copies). the 
wide linear range for quantification (8-9 log decades), the high repro- 
ducibility (CV below 2%) and the minimized risk of cross-contami- 
nation of this system. In this new study we have investigated the 
influence of nucleottde sequence variation in several characterized 
FIV isolates as well as in unknown isolates from naturally infected 
cats. 
Results: We demonstrated that minor mismatches like point 
mutations in the primer or the probe region did not abolish the quan- 
tification completely, but decreased the P C R  efficiency, which 
consequently will influence the viral load estimation. Major mis- 
matches of three or four nucleotide~ lead to complete inhibition of 
real-time P C R  detection. 
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Conclusions: These results demonstrate (1) the higher risk of 
false-negative results with this method, and (2) that accurate viral load 
estimation and especially comparison between viral load data from 
different isolates depends on similarity of the real-time P C R  effi- 
ciency. The final goal will be a real-time P C R  system, which should 
quantiEj a broad range of isolates with equal P C R  efficiencies. 
lp473] Detection of human papillomavirus (HPV) in 
tumorous and inflamed tissues of the eye 
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Objectives: To report on methods for the detection of HPV in 
tumorous and inflamed tissues of the eye putatively infected with 
HPV and on the characterization of HPV types that had not been 
previously detected by commercially available test systems. 
Methods: 33 biopsies of 27 patients suffering from chronic hyper- 
plastic lesions of the lid, conjunctiva and lacrimal drainage system 
were examined using DNA extraction, amplification of HPV-specific 
sequences by nested polymerase chain reaction (PCR), cloning and 
sequencing of the P C R  products. 
Results: 10 HPV types could be detected in 11 biopsies of 8 
patients with histologicly verified papillomas (HPV Sb, 6, 20, 23, 36 
and DL 332 (HPV 5b-related)), seborrheic keratosis (HPV 38), 
molluscum contagiosum (DL 284 (HPV 20-related)), syringoma 
(HPV 20, HPV 23 and DL 332) and dacryocystitis (two putatively 
new types). 
Conclusions: The non-commercial techniques described in this 
study represent important methods for the detection and characteri- 
zation of HPV types and allow an association of HPV types with 
defined inflammations and tumors of the eye. 
Viral diseases 
the activity of the HCMV IE enhancer/promoter in monocytic cells 
via beta-2 adrenergic receptors. Subsequent activation of the CAMP 
pathway involving protein kinase A resulted in enhanced synthesis 
and binding of the transcription factor CREB-1/ATF-1 to the 
CAMP-responsive elements within the IE enhancer. 
Conclusions: These data, for the first time, suggest that HCMV, 
like HSV-1 and VZV, can be activated under stress conditions. 
Usefulness of antigenemia and shell-vial 
culture in the follow-up of renal transplant 
recipients (RT) with CMV disease treated with 
gancyclovir 
J. Reina, E Ballesteros, J. Gasco, X. Bestard, M. Munar. Virology 
Unit, University Hospital Son Dureta, Palma de Mallorca, Spain 
RT recipients who develop a CMV disease should be treated with 
ganciclovir. These patients require a follow-up of their clinical and 
biological response by means of the markers of infection (pp65 anti- 
genemia and viremia). We performed a prospective study of the 
usefulness of these two tests in the follow-up of 15 R T  patients over 
a 6-month post-transplant period. Both tests were used to analyze 69 
blood samples. In 8 patients (53%) the antigenemia (AG) and the 
viremia became negative simultaneously, while in 7 patients (47%) 
the viremia became negative before the AG (p>0.05). The average 
time required by the AG to become negative was 9 days (range 2-21) 
and by the viremia 4 days (range 2-7) (p<O.OS). In the 7 patients 
with negative results obtained first in the shell-vial, this occurred 10.7 
days earlier than in the AG (p<O.OS). In 4 (57%) of these patients AG 
values were equal to or less than the last positive shell-vial, and in 3 
patients (43%) a paradoxical rise in the previous AG value was 
recorded. 
According to these results the viremia (shell-vial culture) is a better 
marker of good clinical evolution and of the therapeutic efficacy of 
ganciclovir treatment. The viremia, which provides earlier and more 
specific results than the AG, which takes longer to become negative, 
is the better biological marker for the follow-up of R T  patients 
treated with ganciclovir. 
I P474 1 Stress-mediated activation of human 
cytomegalovirus in monocytes 
S. Prosch’, C.E.C. Wendt’.’, E? Reinke’, M. Oppert’, D.H. 
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Objectives: To investigate the role of stressful events in HCMV acti- 
vation and influence of catecholamines on regulation of the IE 
enhancer/promoter in monocytic cells. 
Methods: Ten patients with myocardial infarction were moni- 
tored during the first 2 weeks of hospitalization for HCMV antigens 
and HCMV-DNA in PBMC using immunocytology (APAAP tech- 
nique) and DNA-PCR, respectively Catecholamine concentrations 
in plasma were determined by high-performance liquid chromatog- 
raphy. To study the influence of catecholamines on HCMV IE 
enhancer/promoter activity, THP-1 cells were transfected with a 
plasmid construct containing the IE enhancer/promoter upstream of 
the CAT reporter gene. After incubation for 48 h, CAT activity was 
measured in cell extracts by thin layer chromatography 
Results: Of 10 patients investigated, all developed active HCMV 
infection within the first week after hospitalization. Furthermore, the 
active HCMV infection was preceded by a rise of catecholamine 
plasma levels. By in vitro transfection experiments we could demon- 
strate that both epinephrine and norepinephrine specifically elevated 
lp4761 Chronic mental disorders in patients after tick- 
borne encephalitis 
S. Pancewicz’, 1. Gudel-Trochimowicz’, T. Hermanowska- 
Szpakowicz’, R. Poplawska’, S .  Agata’. ‘Department of Parasitic 
Diseases and Neuroinfctions, ’Department o f  Mental Disorders, Medical 
University in Bialystok, Bialystok, Poland 
Objectives: To evaluate the catanmestic mental condition in patients 
3 years after their recovery from tick-borne encephalitis. 
Methods: 43 patients, 23 males (53.5%) and 20 females (46.5%). 
aged 1 8 4 7 ,  were examined. The patients’ mental condition was 
evaluated by means of our own questionnaire and the use of the 
following scales: MMSE, Hamilton Anxiety Rating Scale, Hamilton 
Depression Rating Scale, Trail Making Test A&B, and Becks 
Depression Inventory The results were compared to those in the 
control group. The disorders were classified according to ICD-10 
diagnosis criteria. 
Results: In the examined group, 40 patients (93%) complained of 
subjective ailments. In 54% of the patients, there was decreased famil- 
ial and occupational functioning and 35% of the patients indicated 
intensification of the ailments. The following disorders were 
observed: sadness (61%), hopelessness (26%), decreased energy (54%), 
shakiness inside (58%), diminished ability to think (70%), circum- 
stantiality (42%), lability (51%), dysphoria (40%), poor concentration 
